Biomarkers in Type 2 diabetes: Improving risk stratification with the PreDx® Diabetes Risk Score

Expert Review of Molecular Diagnostics

Volumn 11, Issue 8, 2011, Pages 775-792

  Kolberg, Janice A ^a   Gerwien, Robert W ^a   Watkins, Steve M ^a   Wuestehube, Linda J ^a   Urdea, Mickey ^a  

^a Tethys Bioscience   (United States)

Author keywords

diabetes risk score; predictive biomarkers; risk stratification; Type 2 diabetes

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FERRITIN; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 2 RECEPTOR ALPHA;

CLINICAL PRACTICE; DIET THERAPY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDX DIABETES RISK SCORE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM;

ADIPONECTIN; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; FERRITINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIFE STYLE; MALE; REAGENT KITS, DIAGNOSTIC; RISK; RISK ASSESSMENT;

EID: 80054962800     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.63     Document Type: Review

References (120)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87(1), 4-14 (2010).
2. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic b-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51(9), 2796-2803 (2002).
3. Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359(9323), 2072-2077 (2002).
4. DeFronzo RA, Tripathy D, Schwenke DC et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 364(12), 1104-1115 (2011).
5. Eriksson J, Lindstrom J, Valle T et al. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 42(7), 793-801 (1999).
6. Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368(9541), 1096-1105 (2006).
7. Gillies CL, Abrams KR, Lambert PC et al. Pharmacological and lifestyle interventions to prevent or delay Type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 334(7588), 299 (2007).
8. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346(6), 393-403 (2002).
9. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344(18), 1343-1350 (2001).
10. Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29(6), 1263-1268 (2006).
11. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glucose to Type 2 diabetes. Diabetes Care 30(2), 228-233 (2007).
12. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 31(Suppl. 1), S12-S54 (2008).
13. Selvin E, Crainiceanu CM, Brancati FL Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch. Intern. Med. 167(14), 1545-1551 (2007).
14. Stern MP, Fatehi P, Williams K, Haffner SM. Predicting future cardiovascular disease: do we need the oral glucose tolerance test? Diabetes Care 25(10), 1851-1856 (2002).
15. James C, Bullard KM, Rolka DB et al. Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care 34(2), 387-391 (2011).
16. Olson DE, Rhee MK, Herrick K et al. Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care 33(10), 2184-2189 (2010).
17. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. National Health Statistics Reports No. 13. National Center for Health Statistics, MD, USA (2009).
18. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of Type 2 diabetes and/or cardiovascular disease? Diabetes Care 27(11), 2676-2681 (2004).
19. Aekplakorn W, Bunnag P, Woodward M et al. A risk score for predicting incident diabetes in the Thai population. Diabetes Care 29(8), 1872-1877 (2006).
20. Balkau B, Lange C, Fezeu L et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 31(10), 2056-2061 (2008).
21. Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P. Predicting risk of Type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 338, b880 (2009).
22. Kahn HS, Cheng YJ, TJ Thompson TJ, Imperatore G, Gregg EW. Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years. Ann. Intern. Med. 150(11), 741-751 (2009).
23. Kanaya AM, Wassel Fyr CL, de Rekeneire N et al. Predicting the development of diabetes in older adults: the derivation and validation of a prediction rule. Diabetes Care 28(2), 404-408 (2005).
24. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict Type 2 diabetes risk. Diabetes Care 26(3), 725-731 (2003).
25. Norberg M, Eriksson JW, Lindahl B et al. A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future Type 2 diabetes: OGTT is not needed. J. Intern. Med. 260(3) 263-271 (2006).
26. Schmidt MI, Duncan BB, Bang H et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 28(8), 2013-2018 (2005).
27. Schulze MB, Hoffmann K, Boeing H et al. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of Type 2 diabetes. Diabetes Care 30(3), 510-515 (2007).
28. Wilson PW, Meigs JB, Sullivan L et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch. Intern. Med. 167(10), 1068-1074 (2007).
29. Backlund L, Bring J, Strender L-E. How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients? Primary Health Care Res. Dev. 5, 145-152 (2004).
30. Eaton CB, Galliher JM, McBride PE et al. Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. J. Am. Board Fam. Med. 19(1), 46-53 (2006).
31. Ramachandran S, Labib MH. Hyperlipidaemia and primary prevention of coronary heart disease: are the right patients being treated? J. Cardiovasc. Risk 7(4), 245-249 (2000).
32. Lindstrom J, Peltonen M, Eriksson JG et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care 31(5), 857-862 (2008). Demonstrates that lifestyle intervention is most effective in patients who are at the highest risk of developing Type 2 diabetes.
33. Garber AJ, Handelsman Y, Einhorn D et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr. Pract. 14(7), 933-946 (2008).
34. Karve A, Hayward RA. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults. Diabetes Care 33(11), 2355-2359 (2010). Shows that despite the high prevalence of prediabetes, prevention efforts are lacking, possibly due to a lack of sufficient physician time for chronic disease and preventative care services.
35. Yarnall KS, Ostbye T, Krause KM et al. Family physicians as team leaders: 'time' to share the care. Prev. Chronic Dis. 6(2), A59 (2009).
36. Lyssenko V, Jørgensen T, Gerwien RW et al. Validation of a multi-marker model for the prediction of incident Type 2 diabetes mellitus: combined results of the Inter99 and Botnia studies. Diab. Vasc. Dis. Res. (2011) (In Press). One of three studies describing the clinical validation of the PreDx? Diabetes Risk Score (DRS) in assessing the risk of progressing to Type 2 diabetes within the next 5 years in independent patient populations.
37. Petersen KF, Shulman GI. Etiology of insulin resistance. Am. J. Med. 119(5 Suppl. 1), S10-S16 (2006).
38. Rhodes CJ. Type 2 diabetes - a matter of b-cell life and death? Science 307(5708), 380-384 (2005).
39. Goldfine AB, Bouche C, Parker RA et al. Insulin resistance is a poor predictor of Type 2 diabetes in individuals with no family history of disease. Proc. Natl Acad. Sci. USA 100(5), 2724-2729 (2003).
40. Martin BC, Warram JH, Krolewski AS et al. Role of glucose and insulin resistance in development of Type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340 (8825), 925-929 (1992).
41. Kolberg JA, Jorgensen T, Gerwien RW et al. Development of a Type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care 32(7), 1207-1212 (2009). Publication describing the experimental approach used to identify the most informative biomarkers and develop a Type 2 diabetes risk model.
42. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (7), 1183-1197 (1997).
43. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 34(Suppl. 1), S11-S61 (2011).
44. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 27(Suppl. 1), S5-S10 (2004).
45. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus. WHO, Geneva, Switzerland (1999).
46. Charles MA, Fontbonne A, Thibult N et al. Risk factors for NIDDM in white population. Paris prospective study. Diabetes 40(7), 796-799 (1991).
47. de Vegt F, Dekker JM, Jager A et al. Relation of impaired fasting and postload glucose with incident Type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 285(16), 2109-2113 (2001).
48. Dinneen SF, Maldonado D 3rd, Leibson CL et al. Effects of changing diagnostic criteria on the risk of developing diabetes. Diabetes Care 21(9), 1408-1413 (1998).
49. Edelstein SL, Knowler WC, Bain RP et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46(4), 701-710 (1997).
50. Gabir MM, Hanson RL, Dabelea D et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23(8), 1108-1112 (2000).
51. Vaccaro O, Ruffa G, Imperatore G et al. Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care 22(9), 1490-1493 (1999).
52. Gerstein HC, Santaguida P, Raina P et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res. Clin. Pract. 78(3), 305-312 (2007).
53. Tirosh A, Shai I, Tekes-Manova D et al. Normal fasting plasma glucose levels and Type 2 diabetes in young men. N. Engl. J. Med. 353(14), 1454-1462 (2005).
54. Landgraf R. The relationship of postprandial glucose to HbA1c. Diabetes Metab. Res. Rev. 20(Suppl. 2), S9-S12 (2004).
55. Pradhan AD, Rifai N, Buring JE, Ridker PM. Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am. J. Med. 120(8), 720-727 (2007).
56. Cheng P, Neugaard B, Foulis P, Conlin PR. Hemoglobin A1c as a predictor of incident diabetes. Diabetes Care 34(3), 610-615 (2011).
57. Droumaguet C, Balkau B, Simon D et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2(7), 1619-1625 (2006).
58. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Utility of hemoglobin A1c in predicting diabetes risk. J. Gen. Intern. Med. 19(12), 1175-1180 (2004).
59. Selvin E, Steffes MW, Zhu H et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N. Engl. J. Med. 362(9), 800-811 (2010).
60. Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 30(9), 2399-2400 (2007).
61. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32(7), 1327-1334 (2009).
62. Kilpatrick ES, Bloomgarden ZT, Zimmet PZ. Is haemoglobin A1c a step forward for diagnosing diabetes? BMJ 339, b4432 (2009).
63. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl. 1), S62-S69 (2010).
64. Ferrannini E, Mari A. b cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 47(5), 943-956 (2004).
65. Kahn SE. The relative contributions of insulin resistance and b-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46(1), 3-19 (2003).
66. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 44(8), 929-945 (2001).
67. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of Type 2 diabetes mellitus. J. Clin. Invest. 104(6), 787-794 (1999).
68. Dankner R, Abdul-Ghani MA, Gerber Y et al. Predicting the 20-year diabetes incidence rate. Diabetes Metab. Res. Rev. 23(7), 551-558 (2007).
69. Carnethon MR, Palaniappan LP, Burchfiel CM, Brancati FL, Fortmann SP. Serum insulin, obesity, and the incidence of Type 2 diabetes in black and white adults: the atherosclerosis risk in communities study: 1987-1998. Diabetes Care 25(8), 1358-1364 (2002).
70. Manley SE, Stratton IM, Clark PM, Luzio SD. Comparison of 11 human insulin assays: implications for clinical investigation and research. Clin. Chem. 53(5), 922-932 (2007).
71. Urdea M, Kolberg J, Wilber J et al. Validation of a multimarker model for assessing risk of Type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99). J. Diabetes Sci. Technol. 3(4), 748-755 (2009). One of three studies describing the clinical validation of the PreDx DRS in assessing the risk of progressing to Type 2 diabetes within the next 5 years in independent patient populations.
72. Kadowaki T, Yamauchi T, Kubota N et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116(7) 1784-1792 (2006).
73. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 34(1), 2-11 (2008).
74. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat. Clin. Pract. Cardiovasc. Med. 6(1), 27-35 (2009).
75. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89(6), 2548-2556 (2004).
76. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of Type 2 diabetes: a systematic review and meta-analysis. JAMA 302(2), 179-188 (2009). Meta-analysis of 13 prospective studies showing that higher adiponectin levels are associated with a lower risk of Type 2 diabetes.
77. Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for Type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia 51(6), 926-940 (2008).
78. de Rooij SR, Nijpels G, Nilsson PM et al. Low-grade chronic inflammation in the relationship between insulin sensitivity and cardiovascular disease (RISC) population: associations with insulin resistance and cardiometabolic risk profile. Diabetes Care 32(7), 1295-1301 (2009).
79. Cook JR, Semple RK. Hypoadiponectinemia - cause or consequence of human 'insulin resistance'? J. Clin. Endocrinol. Metab. 95(4), 1544-1554 (2010).
80. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55(1), 249-259 (2006).
81. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279(18), 1477-1482 (1998).
82. Lin J, Glynn RJ, Rifai N et al. Inflammation and progressive nephropathy in Type 1 diabetes in the diabetes control and complications trial. Diabetes Care 31(12), 2338-2343 (2008).
83. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118(9), 2992-3002 (2008).
84. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 132(6), 2169-2180 (2007).
85. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 582(1), 97-105 (2008).
86. Greenfield JR, Campbell LV. Relationship between inflammation, insulin resistance and Type 2 diabetes: 'cause or effect'? Curr. Diabetes Rev. 2(2), 195-211 (2006).
87. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest. 111(12), 1805-1812 (2003).
88. Freeman DJ, Norrie J, Caslake MJ et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51(5), 1596-1600 (2002).
89. WOSCOPS Study Group. Screening experience and baseline characteristics in the West Scotland Study. Am. J. Cardiol. 76(7), 485-491 (1995).
90. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus. JAMA 286(3), 327-334 (2001).
91. Doi Y, Kiyohara Y, Kubo M et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 28(10), 2497-2500 (2005).
92. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of Type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51(4), 1131-1137 (2002).
93. Brunner EJ, Kivimaki M, Witte DR et al. Inflammation, insulin resistance, and diabetes - Mendelian randomization using CRP haplotypes points upstream. PLoS Med. 5(8), e155 (2008).
94. Dehghan A, Kardys I, de Maat MP et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56(3) 872-878 (2007).
95. Lee CC, Adler AI, Sandhu MS et al. Association of C-reactive protein with Type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 52(6), 1040-1047 (2009). A prospective study and literature-based meta-analysis of 16 published studies examining the association between C-reactive protein and incident diabetes.
96. Rafiq S, Melzer D, Weedon MN et al. Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of Type 2 diabetes. Diabetologia 51(12), 2205-2213 (2008).
97. Doganay S, Evereklioglu C, Er H et al. Comparison of serum NO, TNF-a, IL-1b, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond.) 16(2), 163-170 (2002).
98. Giordano C, Galluzzo A, Marco A et al. Increased soluble interleukin-2 receptor levels in the sera of Type 1 diabetic patients. Diabetes Res. 8(3), 135-138 (1988).
99. Greenberg SJ, Marcon L, Hurwitz BJ, Waldmann TA, Nelson DL. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N. Engl. J. Med. 319(15), 1019-1020 (1988).
100. Makis AC, Galanakis E, Hatzimichael EC et al. Serum levels of soluble interleukin-2 receptor a (sIL-2Ra) as a predictor of outcome in brucellosis. J. Infect. 51(3), 206-210 (2005).
101. Pereira FO, Frode TS, Medeiros YS. Evaluation of tumour necrosis factor a, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in Type 2 diabetes mellitus. Med. Inflamm. 2006(1), 39062 (2006).
102. Maier LM, Lowe CE, Cooper J et al. IL2RA genetic heterogeneity in multiple sclerosis and Type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 5(1), e1000322 (2009).
103. Kitabchi AE, Stentz FB, Umpierrez GE. Diabetic ketoacidosis induces in vivo activation of human T-lymphocytes. Biochem. Biophys. Res. Commun. 315(2), 404-407 (2004).
104. Swaminathan S, Fonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care 30(7), 1926-1933 (2007).
105. Jiang R, Manson JE, Meigs JB et al. Body iron stores in relation to risk of Type 2 diabetes in apparently healthy women. JAMA 291(6), 711-717 (2004).
106. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 22(12), 1978-1983 (1999).
107. Forouhi NG, Harding AH, Allison M et al. Elevated serum ferritin levels predict new-onset Type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50(5), 949-956 (2007).
108. Jehn ML, Guallar E, Clark JM et al. Prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Epidemiol. 165(9), 1047-1054 (2007).
109. Acton RT, Barton JC, Passmore LV et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 29(9) 2084-2089 (2006).
110. Buijsse B, Simmons RK, Griffin SJ, Schulze MB. Risk assessment tools for identifying individuals at risk of developing Type 2 diabetes. Epidemiol. Rev. 33(1), 46-62 (2011).
111. Kolberg J, Wagenknecht L, Rowe MW, Bergman RN. Performance of a multi-marker diabetes risk score on the Insulin Resistance Atherosclerosis Study (IRAS), a multi-ethnic US cohort. Presented at: 6th World Congress on Prevention of Diabetes and its Complications. Dresden, Germany, 8-10 April 2010. One of three studies describing the clinical validation of the PreDX DRS in assessing the risk of progressing to Type 2 diabetes within the next 5 years in independent patient populations.
112. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16), 1640-1645 (2009).
113. Lorenzo C, Wagenknecht LE, D'Agostino RB Jr et al. Insulin resistance, b-cell dysfunction, and conversion to Type 2 diabetes in a multiethnic population: the Insulin Resistance Atherosclerosis Study. Diabetes Care 33(1), 67-72 (2010).
114. Watkins SM, Rowe MW, Kolberg JA, Bergman RN, Wagenknecht LE. A multi-marker risk score predicts insulin sensitivity and b cell function-driven Type 2 diabetes from a fasting blood sample. Presented at: European Association for the Study of Diabetes (EASD) 46th Annual Meeting. Stockholm, Sweden, 20-24 September 2010.
115. Markowitz SM, Park ER, Delahanty LM, O'Brien KE, Grant RW. Perceived impact of diabetes genetic risk testing among patients at high phenotypic risk for Type 2 diabetes. Diabetes Care 34(3), 568-573 (2011).
116. Xiang AH, Kolberg JA, Gerwein RW et al. Evaluation of change in a multi-marker diabetes risk score (DRS) in response to Troglitazone treatment. Presented at: 3rd International Conference on Prediabetes and Metabolic Syndrome. Nice, France, 1-4 April 2009.
117. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann. Intern. Med. 143(4), 251-264 (2005). A study based on data from the Diabetes Prevention Program trial indicating that lifestyle and pharmaceutical interventions for people at high risk for diabetes may be too expensive for health plans or a national program.
118. Herman WH, Hoerger TJ, Brandle M et al. The cost-effectiveness of lifestyle modification or metformin in preventing Type 2 diabetes in adults with impaired glucose tolerance. Ann. Intern. Med. 142(5), 323-332 (2005). A study based on data from the Diabetes Prevention Program trial showing that lifestyle and drug interventions were cost effective.
119. Sullivan SD, Garrison LP, Rinde H, Kolberg J, Moler EJ. Cost-effectiveness of risk stratification for preventing Type 2 diabetes using a multi-marker diabetes risk score. J. Med. Econ. 14(5), 609-616 (2011).
120. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 27(6), 1487-1495 (2004).